IL315941A - Uses of farnesoid x receptor agonists - Google Patents
Uses of farnesoid x receptor agonistsInfo
- Publication number
- IL315941A IL315941A IL315941A IL31594124A IL315941A IL 315941 A IL315941 A IL 315941A IL 315941 A IL315941 A IL 315941A IL 31594124 A IL31594124 A IL 31594124A IL 315941 A IL315941 A IL 315941A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- patient
- amino acid
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263333287P | 2022-04-21 | 2022-04-21 | |
| US202263381752P | 2022-10-31 | 2022-10-31 | |
| PCT/US2023/019448 WO2023205447A2 (en) | 2022-04-21 | 2023-04-21 | Uses of farnesoid x receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL315941A true IL315941A (en) | 2024-11-01 |
Family
ID=88420596
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL315941A IL315941A (en) | 2022-04-21 | 2023-04-21 | Uses of farnesoid x receptor agonists |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250288600A1 (https=) |
| EP (1) | EP4511012A2 (https=) |
| JP (1) | JP2025513289A (https=) |
| KR (1) | KR20250006156A (https=) |
| CN (1) | CN119136794A (https=) |
| AU (1) | AU2023257308A1 (https=) |
| CA (1) | CA3249500A1 (https=) |
| IL (1) | IL315941A (https=) |
| MX (1) | MX2024012966A (https=) |
| WO (1) | WO2023205447A2 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4611888A1 (en) * | 2022-10-31 | 2025-09-10 | Intercept Pharmaceuticals, Inc. | Uses of farnesoid x receptor agonists |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017004708A2 (pt) * | 2014-09-12 | 2017-12-05 | Tobira Therapeutics Inc | terapia de combinação de cenicriviroc para o tratamento de fibrose |
| PE20180690A1 (es) * | 2015-04-27 | 2018-04-23 | Intercept Pharmaceuticals Inc | Composiciones de acido obeticolico y metodos de uso |
| ES2874682T3 (es) * | 2016-03-11 | 2021-11-05 | Intercept Pharmaceuticals Inc | Derivados de 3-desoxi y composiciones farmacéuticas de los mismos |
| BR112019027458A2 (pt) * | 2017-06-23 | 2020-07-07 | Intercept Pharmaceuticals, Inc. | métodos e intermediários para a preparação de derivados de ácidos biliares |
-
2023
- 2023-04-21 WO PCT/US2023/019448 patent/WO2023205447A2/en not_active Ceased
- 2023-04-21 AU AU2023257308A patent/AU2023257308A1/en active Pending
- 2023-04-21 US US18/858,674 patent/US20250288600A1/en active Pending
- 2023-04-21 IL IL315941A patent/IL315941A/en unknown
- 2023-04-21 CA CA3249500A patent/CA3249500A1/en active Pending
- 2023-04-21 JP JP2024561602A patent/JP2025513289A/ja active Pending
- 2023-04-21 KR KR1020247038272A patent/KR20250006156A/ko active Pending
- 2023-04-21 EP EP23792602.7A patent/EP4511012A2/en active Pending
- 2023-04-21 CN CN202380035124.0A patent/CN119136794A/zh active Pending
-
2024
- 2024-10-21 MX MX2024012966A patent/MX2024012966A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023205447A3 (en) | 2024-04-04 |
| US20250288600A1 (en) | 2025-09-18 |
| CA3249500A1 (en) | 2023-10-26 |
| WO2023205447A2 (en) | 2023-10-26 |
| MX2024012966A (es) | 2024-11-08 |
| KR20250006156A (ko) | 2025-01-10 |
| EP4511012A2 (en) | 2025-02-26 |
| JP2025513289A (ja) | 2025-04-24 |
| AU2023257308A1 (en) | 2024-10-10 |
| CN119136794A (zh) | 2024-12-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5869469B2 (ja) | 鉄が病因に関与する肝臓疾患の処置 | |
| JP3721196B2 (ja) | 新生物疾患および自己免疫疾患の治療または予防のためのマグネシウムベースの製品の使用 | |
| IL131484A (en) | Treatment of cardiomyopathy | |
| JP2025143324A5 (https=) | ||
| JP2000511190A (ja) | 外傷に起因する出血に見舞われたヒトにおけるｂｐｉタンパク質産物の治療用途 | |
| JP2022542151A (ja) | ＦＧＦ２１ Ｆｃ融合タンパク質、ＧＬＰ－１ Ｆｃ融合タンパク質、それらの併用治療剤および使用 | |
| JP2022542830A (ja) | Ｅｙｐ００１を使用した改善された処置 | |
| IL315941A (en) | Uses of farnesoid x receptor agonists | |
| WO2023231730A2 (zh) | 使用mazdutide的治疗方法 | |
| Sloth et al. | Acute renal insufficiency during treatment with azathioprine | |
| JP3838034B2 (ja) | Ｃ型肝炎治療効果の改善剤及びその応用 | |
| Sistino et al. | Systemic inflammatory response syndrome (SIRS) following emergency cardiopulmonary bypass: a case report and literature review | |
| CN111939179A (zh) | 眼镜蛇蛇毒或其提取物在制备降尿酸和/或抗痛风性关节炎的药物中的应用 | |
| JP2025513289A5 (https=) | ||
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 | |
| WO2024023745A1 (en) | Treatment for acute organ injury using cd39, recombinant cd39 | |
| EP1305012A2 (en) | A method for treating celiac disease | |
| CA2340257A1 (en) | Treatment of disease states | |
| CA3171367A1 (en) | Methods for treating fibrosis using pkm2 activators | |
| JP2006515011A (ja) | Ｈｃｖ併用療法 | |
| Lahaye et al. | Vanishing pulmonary hypertension in mixed connective tissue disease | |
| JPWO2007013677A1 (ja) | インターフェロン作用物質の活性増強剤 | |
| JP2010208946A (ja) | 関節リウマチの予防・治療剤 | |
| US5750501A (en) | Method and composition for treatment of patients having decompensated liver disease | |
| JPWO2006033453A1 (ja) | インターフェロン作用物質の活性増強剤 |